González Santiago, Santiago | Oncología

Resultados: 37
Tipo Título / Nombre Autor(es) Año
Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients Llop-Guevara A, Torres-Esquius S, Romey M, Gutiérrez-Enriquez S..., González Santiago S 2022
Sapanisertib Plus Fulvestrant in Post-Menopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer After Progression on Aromatase Inhibitor García-Sáenz JÁ, Martínez-Jáñez N, Cubedo R, Jerez Y, Lahuerta A, González-Santiago S, Ferrer N, Ramos M, Alonso-Romero JL, Antón A, Carrasco E, Chen J, Neuwirth R, Galinsky K, Vincent S, Leonard EJ, Slamon D 2022
Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy Villacampa G, Paré L, Hernando C..., González Santiago S 2021
Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa) Gavilá Gregori J, López Miranda E, Escrivá de Romani S..., González Santiago S 2021
Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH Vaz Batista M Pérez García JM Llombart Cussac A Cortez P Ruiz Borrego M... González Santiago S Gion M 2021
SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+ metastatic breast cancer (MBC) Ciruelos EM Pernas S Perelló A López A Salvador Bofill FJ... González Santiago S Sanfeliu E 2021
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E ..., González-Santiago S 2021
Resultados de calidad de vida (CV) del estudio PEARL (GEICAM/2013-02) en pacientes con cáncer de mama metastásico (CMM), Receptor Hormonal (RH)- positivo/HER2-negativo, tratadas con Palbociclib (PAL) más terapia Endocrina (TE) versus Capecitabina (CAP) Bermejo B, Lang I, Gil-Gil M, Ruíz-Borrego M, Ciruelos E..., González S, González S, Rodríguez CA, Servitja S, Rossmann D 2020
Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with ER+/HER2- advanced or metastatic breast cancer that previously progressed during or after aromatase inhibitor therapy (NCT02756364) García Sáenz JA, Martínez Jáñez N, Martín M, Lahuerta Martínez A, Gónzalez-Santiago S, Ferrer Tur N, Ramos Váquez M [et.al] 2020
Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients Cortés J, Ciruelos E, Pérez-García J, Albanell J, García-Estévez L..., González S, Álvarez I, Llombart A 2020